Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The pharmacokinetics and tolerability of selexipag in patients with severe renal impairment and also in volunteers

Trial Profile

The pharmacokinetics and tolerability of selexipag in patients with severe renal impairment and also in volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Apr 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Selexipag (Primary)
  • Indications Pulmonary hypertension
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 07 Apr 2016 Pooled analysis of 2 trials, including this and another study (see CTP 700238645) were published in the British Journal of Clinical Pharmacology.
    • 13 Nov 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top